cannabidiol/isoflurane (IHL-216A) / Incannex - LARVOL DELTA

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A (PRNewswire) - "Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A. Engagement of Curia follows achievement of 'proof-of-concept' formulation development. A patent has been filed on the composition of IHL-216A. The first cGMP batch of IHL-216A manufactured at Curia will be used in a phase 1 clinical trial. Incannex is targeting a pre-IND meeting with FDA in Q3 2022 to discuss the most efficient clinical trial development plan to achieve commercialisation for IHL-216A. "

Commercial • FDA event • CNS Disorders

"$IXHL Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A https://t.co/wSluyDFYhp" (@stock_titan)

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement (PRNewswire) - "Incannex announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion. Incannex announced that IHL-216A was observed to have a strong neuroprotective effect in a widely known model of sports concussion....The Incannex scientific team is targeting a pre-IND meeting with FDA in Q3 2022 to discuss the Company's intention to conduct an expedited clinical trial program required for a new drug application and marketing approval. IHL-216A drug formulation development required for in-human studies is also nearing a conclusion following an extensive research and development process commenced in June 2021."

Preclinical • CNS Disorders

"$IXHL Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion https://t.co/G0kcDCtKpw" (@stock_titan)

Preclinical